Angiogenic tyrosyl tRNA synthetase compositions and methods
The present invention provides an isolated tyrosyl tRNA synthetase (TyrRS) polypeptide variant which comprises (a) a Rossmann fold region or a portion thereof, preferably including an 5 coil; and (b) an anticodon recognition domain or portion thereof, preferably including an 14 coil. Preferably, the 5 coil and the 14 coil have a greater spatial separation in the tertiary structure of the variant compared to the corresponding spatial separation in native human TyrRS. The variant preferably comprises an amino acid residue sequence identity of at least about 50% compared to the amino acid residue sequence of human TyrRS (SEQ ID NO: 3), includes at least one non-conservative amino acid residue sequence of human TyrRS, and preferably presents an exposed ELR motif in the 5 coil on an external portion of the tertiary structure of the polypeptide. A preferred TyrRS protein variant comprises the amino acid residue sequence of SEQ ID NO: 4 or a portion thereof. The proteins and protein fragments of the invention are angiogenic and are useful for stimulating angiogenesis in mammalian tissues.
1. An isolated tyrosyl tRNA synthetase (TyrRS) polypeptide variant comprising the amino acid residue sequence of SEQ ID NO: 4 or a fragment thereof, wherein the fragment of SEQ ID NO: 4 comprises at least all of residues 1 through 364 of SEQ ID NO: 4, and wherein residue X at position 341 of SEQ ID NO: 4 is selected from the group consisting of a glycine residue, an alanine residue, a valine residue, a leucine residue, an isoleucine residue, a methionine residue, and a proline residue.
2. The TyrRS polypeptide variant of claim 1 wherein residue X at position 341 of SEQ ID NO: 4 is an amino acid residue selected from the group consisting of a glycine residue, an alanine residue, and a proline residue.
3. The TyrRS polypeptide variant of claim 1 wherein residue X at position 341 of SEQ ID NO: 4 is an alanine residue.
4. An isolated tyrosyl tRNA synthetase (TyrRS) polypeptide variant consisting of the amino acid residue sequence of SEQ ID NO: 4, wherein residue X at position 341 of SEQ ID NO: 4 is selected from the group consisting of a glycine residue, an alanine residue, a phenylalanine residue, a valine residue, a leucine residue, an isoleucine residue, a methionine residue, and a proline residue.
5. The TyrRS polypeptide variant of claim 4 wherein residue X at position 341 of SEQ ID NO: 4 is selected from the group consisting of a glycine residue, an alanine residue, and a proline residue.
6. The TyrRS polypeptide variant of claim 4 wherein residue X at position 341 of SEQ ID NO: 4 is an alanine residue.